Bicara Therapeutics Inc. 4

Ryan Cohlhepp, President, COO & Interim CEO of Bicara Therapeutics Inc. (BCAX), exercised 17,500 options and sold 17,500 shares of common stock on September 8, 2026 under a Rule 10b5-1 plan.

On September 8, 2026, Bicara Therapeutics Inc. President, COO & Interim CEO Ryan Cohlhepp exercised 17,500 stock options at $3.7898 per share, acquiring 17,500 shares of common stock, and on the same day sold a total of 17,500 shares in two open-market transactions under a Rule 10b5-1 trading plan: 14,058 shares at a weighted average price of $22.7666 and 3,442 shares at a weighted average price of $23.4349. The option exercise appears to be part of a scheduled vesting plan, with the underlying option originally granted on April 5, 2023 and vesting in sixteen equal quarterly installments. After these transactions, Cohlhepp directly owned 181,641 shares of Bicara Therapeutics common stock, reflecting continued substantial equity exposure despite the sale of shares associated with the option exercise.

Filing Facts

CIK

2023658

Ticker

BCAX

Form

4

Source Type

fda

Accession

0001470831-26-000883

Alert Tier

6